MTOR and breast carcinoma: The clinical development of PI3K/AKT/mTOR targeted therapies for breast cancer treatment and the increasing appreciation that PI3K/AKT/mTOR contributes to endocrine resistance emphasises the relevance of studying the pathway in cell line or PDO models.